Gilead Reveals Leadership Transition As Milligan Takes CEO Role
This article was originally published in Scrip
Gilead Sciences Inc. faced a lot of bad news related to its hepatitis C drugs during the last week of January, so there might have been a better time to announce a changing of the guard in the company's C-suite, no matter how much shareholders anticipated the succession plan.
You may also be interested in...
While Milligan’s year-end departure topped the news, Gilead posted solid sales growth for Yescarta, got the HIV franchise back to growth and saw HCV’s decline largely stabilize. CSO McHutchison, meanwhile, predicted that selonsertib could be first to market in NASH.
Median tenure of large cap US biotech CEOs has decreased from 11 years in 2007 to one year in 2017, Leerink analyst Geoffrey Porges determined in an analysis of seven biotechs over 15 years.
Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.